Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

Wenting Wu, Kathleen R. Lamborn, Jan C. Buckner, Paul J. Novotny, Susan M. Chang, Judith R. O'Fallon, Kurt A. Jaeckle, Michael D. Prados

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The purpose of this study is to determine prognostic factors in patients with high-grade recurrent glioma for 3 outcome variables (overall survival, progression-free survival [PFS], and PFS rate 6 months after study registration [PFS6]). Data from 15 North Central Cancer Treatment Group (NCCTG) trials (n = 469, 1980-2004) and 12 North American Brain Tumor Consortium (NABTC) trials (n = 596, 1998-2002) were included. Eighteen prognostic variables were considered including type of treatment center (community/academic) and initial low-grade histology (yes/no). Recursive partitioning analysis (RPA), Cox proportional hazards, and logistic regression models with bootstrap resampling were used to identify prognostic variables. Longer survival was associated with last known grade (Grade) of III, younger age, ECOG performance score (PS) of 0, shorter time from initial diagnosis (DxTime), and no baseline steroid use. Factors associated with longer PFS were Grade III and shorter DxTime. For patients without temozolomide as part of the treatment regimen, the only factor associated with better PFS6 was Grade III, although DxTime was important in RPA and PS was important in logistic regression. Grade was the most important prognostic factor for all three endpoints regardless of the statistical method used. Other important variables for one or more endpoints included age, PS, and DxTime. Neither type of treatment center nor initial low-grade histology was identified as a major predictor for any endpoint.

Original languageEnglish (US)
Pages (from-to)164-172
Number of pages9
JournalNeuro-Oncology
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

Brain Neoplasms
Glioma
Statistical Factor Analysis
Joints
Disease-Free Survival
Logistic Models
temozolomide
Neoplasms
Histology
Survival
Therapeutics
Survival Rate
Steroids

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Wu, W., Lamborn, K. R., Buckner, J. C., Novotny, P. J., Chang, S. M., O'Fallon, J. R., ... Prados, M. D. (2010). Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology, 12(2), 164-172. https://doi.org/10.1093/neuonc/nop019
Wu, Wenting ; Lamborn, Kathleen R. ; Buckner, Jan C. ; Novotny, Paul J. ; Chang, Susan M. ; O'Fallon, Judith R. ; Jaeckle, Kurt A. ; Prados, Michael D. / Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. In: Neuro-Oncology. 2010 ; Vol. 12, No. 2. pp. 164-172.
@article{816e3e8eeef7434ca05ca3690c95cb49,
title = "Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma",
abstract = "The purpose of this study is to determine prognostic factors in patients with high-grade recurrent glioma for 3 outcome variables (overall survival, progression-free survival [PFS], and PFS rate 6 months after study registration [PFS6]). Data from 15 North Central Cancer Treatment Group (NCCTG) trials (n = 469, 1980-2004) and 12 North American Brain Tumor Consortium (NABTC) trials (n = 596, 1998-2002) were included. Eighteen prognostic variables were considered including type of treatment center (community/academic) and initial low-grade histology (yes/no). Recursive partitioning analysis (RPA), Cox proportional hazards, and logistic regression models with bootstrap resampling were used to identify prognostic variables. Longer survival was associated with last known grade (Grade) of III, younger age, ECOG performance score (PS) of 0, shorter time from initial diagnosis (DxTime), and no baseline steroid use. Factors associated with longer PFS were Grade III and shorter DxTime. For patients without temozolomide as part of the treatment regimen, the only factor associated with better PFS6 was Grade III, although DxTime was important in RPA and PS was important in logistic regression. Grade was the most important prognostic factor for all three endpoints regardless of the statistical method used. Other important variables for one or more endpoints included age, PS, and DxTime. Neither type of treatment center nor initial low-grade histology was identified as a major predictor for any endpoint.",
author = "Wenting Wu and Lamborn, {Kathleen R.} and Buckner, {Jan C.} and Novotny, {Paul J.} and Chang, {Susan M.} and O'Fallon, {Judith R.} and Jaeckle, {Kurt A.} and Prados, {Michael D.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1093/neuonc/nop019",
language = "English (US)",
volume = "12",
pages = "164--172",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "2",

}

Wu, W, Lamborn, KR, Buckner, JC, Novotny, PJ, Chang, SM, O'Fallon, JR, Jaeckle, KA & Prados, MD 2010, 'Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma', Neuro-Oncology, vol. 12, no. 2, pp. 164-172. https://doi.org/10.1093/neuonc/nop019

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. / Wu, Wenting; Lamborn, Kathleen R.; Buckner, Jan C.; Novotny, Paul J.; Chang, Susan M.; O'Fallon, Judith R.; Jaeckle, Kurt A.; Prados, Michael D.

In: Neuro-Oncology, Vol. 12, No. 2, 01.02.2010, p. 164-172.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

AU - Wu, Wenting

AU - Lamborn, Kathleen R.

AU - Buckner, Jan C.

AU - Novotny, Paul J.

AU - Chang, Susan M.

AU - O'Fallon, Judith R.

AU - Jaeckle, Kurt A.

AU - Prados, Michael D.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - The purpose of this study is to determine prognostic factors in patients with high-grade recurrent glioma for 3 outcome variables (overall survival, progression-free survival [PFS], and PFS rate 6 months after study registration [PFS6]). Data from 15 North Central Cancer Treatment Group (NCCTG) trials (n = 469, 1980-2004) and 12 North American Brain Tumor Consortium (NABTC) trials (n = 596, 1998-2002) were included. Eighteen prognostic variables were considered including type of treatment center (community/academic) and initial low-grade histology (yes/no). Recursive partitioning analysis (RPA), Cox proportional hazards, and logistic regression models with bootstrap resampling were used to identify prognostic variables. Longer survival was associated with last known grade (Grade) of III, younger age, ECOG performance score (PS) of 0, shorter time from initial diagnosis (DxTime), and no baseline steroid use. Factors associated with longer PFS were Grade III and shorter DxTime. For patients without temozolomide as part of the treatment regimen, the only factor associated with better PFS6 was Grade III, although DxTime was important in RPA and PS was important in logistic regression. Grade was the most important prognostic factor for all three endpoints regardless of the statistical method used. Other important variables for one or more endpoints included age, PS, and DxTime. Neither type of treatment center nor initial low-grade histology was identified as a major predictor for any endpoint.

AB - The purpose of this study is to determine prognostic factors in patients with high-grade recurrent glioma for 3 outcome variables (overall survival, progression-free survival [PFS], and PFS rate 6 months after study registration [PFS6]). Data from 15 North Central Cancer Treatment Group (NCCTG) trials (n = 469, 1980-2004) and 12 North American Brain Tumor Consortium (NABTC) trials (n = 596, 1998-2002) were included. Eighteen prognostic variables were considered including type of treatment center (community/academic) and initial low-grade histology (yes/no). Recursive partitioning analysis (RPA), Cox proportional hazards, and logistic regression models with bootstrap resampling were used to identify prognostic variables. Longer survival was associated with last known grade (Grade) of III, younger age, ECOG performance score (PS) of 0, shorter time from initial diagnosis (DxTime), and no baseline steroid use. Factors associated with longer PFS were Grade III and shorter DxTime. For patients without temozolomide as part of the treatment regimen, the only factor associated with better PFS6 was Grade III, although DxTime was important in RPA and PS was important in logistic regression. Grade was the most important prognostic factor for all three endpoints regardless of the statistical method used. Other important variables for one or more endpoints included age, PS, and DxTime. Neither type of treatment center nor initial low-grade histology was identified as a major predictor for any endpoint.

UR - http://www.scopus.com/inward/record.url?scp=75849127029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75849127029&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nop019

DO - 10.1093/neuonc/nop019

M3 - Article

C2 - 20150383

AN - SCOPUS:75849127029

VL - 12

SP - 164

EP - 172

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 2

ER -

Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O'Fallon JR et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology. 2010 Feb 1;12(2):164-172. https://doi.org/10.1093/neuonc/nop019